Citadel Advisors
GNMX

Citadel Advisors’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Citadel Advisors’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-21,000
Closed -$26K – 10123
2018
Q3 		$26K Buy
+21,000
New +$23.5K ﹤0.01% 8969
2017
Q2 		– Sell
-23,600
Closed -$44K – 8354
2017
Q1 		$44K Sell
23,600
-3,600
-13% -$16.3K ﹤0.01% 7072
2016
Q4 		$141K Buy
+27,200
New +$143K ﹤0.01% 6537

Other funds holding GNMX

AMCA
Arthur M. Cohen & Associates Northbrook, Illinois $563M AUM 20.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Citadel Advisors's GNMX Position: Q4 2019 in Review

Citadel Advisors sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2019, closing a stake of 160,264 shares — an estimated $24K sold.

Citadel Advisors first reported a position in GNMX in Q4 2016 and held it in 10 quarters. The position peaked at $145K in Q4 2016. 28 funds tracked by Wall St. Rank hold GNMX as of Q4 2019.

  • Citadel Advisors reported no remaining Aevi Genomic Medicine Inc position as of Q4 2019 after selling out during the quarter.
  • Citadel Advisors sold 160,264 Aevi Genomic Medicine Inc shares in Q4 2019, an estimated $24K.
  • Citadel Advisors first reported a position in Aevi Genomic Medicine Inc in Q4 2016 and held it in 10 quarters.
  • Citadel Advisors's Aevi Genomic Medicine Inc position peaked at $145K in Q4 2016.
  • 28 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2019.

Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.